Opinion of the European Economic and Social Committee on (a) the communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions — Reform of the pharmaceutical legislation and measures addressing antimicrobial resistance (COM(2023) 190 final), (b) the proposal for a Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a One Health approach (COM(2023) 191 final — 2023/0125 (NLE)), (c) the proposal for a Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC (COM(2023) 192 final — 2023/0132 (COD)) and (d) the proposal for a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006 (COM(2023) 193 final — 2023/0131 (COD))